View Item 

Show simple item record

Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study
dc.contributor.authorO’Leary, Jacqueline G.
dc.contributor.authorFontana, Robert J.
dc.contributor.authorBrown, Kimberly
dc.contributor.authorBurton, James R.
dc.contributor.authorFirpi‐morell, Roberto
dc.contributor.authorMuir, Andrew
dc.contributor.authorO’Brien, Christopher
dc.contributor.authorRabinovitz, Mordechai
dc.contributor.authorReddy, Rajender
dc.contributor.authorRyan, Robert
dc.contributor.authorShprecher, Adam
dc.contributor.authorVilladiego, Shirley
dc.contributor.authorPrabhakar, Avinash
dc.contributor.authorBrown, Robert S.
dc.date.accessioned2017-04-13T20:34:53Z
dc.date.available2018-05-04T20:56:58Zen
dc.date.issued2017-02
dc.identifier.citationO’Leary, Jacqueline G.; Fontana, Robert J.; Brown, Kimberly; Burton, James R.; Firpi‐morell, Roberto ; Muir, Andrew; O’Brien, Christopher; Rabinovitz, Mordechai; Reddy, Rajender; Ryan, Robert; Shprecher, Adam; Villadiego, Shirley; Prabhakar, Avinash; Brown, Robert S. (2017). "Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study." Transplant International 30(2): 196-208.
dc.identifier.issn0934-0874
dc.identifier.issn1432-2277
dc.identifier.urihttps://hdl.handle.net/2027.42/136282
dc.publisherWiley Periodicals, Inc.
dc.publisherMerck & Co., Inc.
dc.subject.otherinfectionâ hepatitis B, C
dc.subject.otherliver clinicalâ other
dc.titleEfficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136282/1/tri12896.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136282/2/tri12896_am.pdf
dc.identifier.doi10.1111/tri.12896
dc.identifier.sourceTransplant International
dc.identifier.citedreferenceSaab S, Greenberg A, Li E, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int 2015; 35: 2442.
dc.identifier.citedreferenceBurton JR Jr, O’Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with proteaseâ inhibitor triple therapy. J Hepatol 2014; 61: 508.
dc.identifier.citedreferenceFaisal N, Yoshida EM, Bilodeau M, et al. Protease inhibitorâ based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014; 13: 525.
dc.identifier.citedreferenceKaneko J, Sugawara Y, Yamaguchi T, et al. Telaprevirâ based triple therapy for hepatitis C null responders among living donor liver transplant recipients. Biosci Trends 2014; 8: 339.
dc.identifier.citedreferenceKwo PY, Mantry PS, Coakley E, et al. An interferonâ free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375.
dc.identifier.citedreferenceCharlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108.
dc.identifier.citedreferencePungpapong S, Aqel B, Leise M, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880.
dc.identifier.citedreferenceGutierrez JA, Carrion AF, Avalos D, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21: 823.
dc.identifier.citedreferenceKhemichian S, Lee B, Kahn J, et al. Sofosbuvir and simeprevir therapy for recurrent hepatitis C infection after liver transplantation. Transplant Direct 2015; 1: 1.
dc.identifier.citedreferenceCharlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649.
dc.identifier.citedreferencePoordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or postâ liver transplant recurrence. Hepatology 2016; 63: 1493.
dc.identifier.citedreferenceREBETOL ® (ribavirin) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2016.
dc.identifier.citedreferenceCurry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an openâ label study. Gastroenterology 2015; 148: 100.
dc.identifier.citedreferenceBanerjee D, Reddy KR. Review article: safety and tolerability of directâ acting antiâ viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016; 43: 674.
dc.identifier.citedreferenceShafran SD. The hepatitis C genotype 1 paradox: cost per treatment is increasing, but cost per cure is decreasing. Can J Gastroenterol Hepatol 2015; 29: 46.
dc.identifier.citedreferenceOLYSIO ® (simeprevir) [package insert]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; October 2015.
dc.identifier.citedreferenceOLYSIO ® (simeprevir) [EU SmPC]. Beerse, Belgium: Janssenâ Cilag International NV.
dc.identifier.citedreferenceBrown RS Jr, O’Leary JG, Reddy KR, et al. Interferonâ free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCVâ TARGET. Liver Transpl 2016; 22: 24.
dc.identifier.citedreferenceHolmberg SD, Lu M, Rupp LB, et al. Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. Clin Infect Dis 2013; 57: 240.
dc.identifier.citedreferenceHARVONI ® (ledipasvir and sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; February 2016.
dc.identifier.citedreferenceSOVALDI ® (sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; August 2015.
dc.identifier.citedreferenceEuroQol Group. EuroQolâ a new facility for the measurement of healthâ related quality of life. Health Policy 1990; 16: 199.
dc.identifier.citedreferenceLawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in nonâ responders to pegylated interferon and ribavirin and treatmentâ naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756.
dc.identifier.citedreferenceGao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013; 3: 514.
dc.identifier.citedreferencePoveda E, Wyles DL, Mena A, Pedreira JD, Castroâ Iglesias A, Cachay E. Update on hepatitis C virus resistance to directâ acting antiviral agents. Antiviral Res 2014; 108: 181.
dc.identifier.citedreferenceHézode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with HCV GT1 or 4 who previously failed a daclatasvirâ containing regimen. Hepatology 2016; 63: 1809.
dc.identifier.citedreferenceOuwerkerkâ Mahadevan S, Snoeys J, Peeters M, Beumontâ Mauviel M, Simion A. Drugâ drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet 2016; 55: 197.
dc.identifier.citedreferenceKugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159.
dc.identifier.citedreferenceKwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1â infected patients without cirrhosis: OPTIMISTâ 1, a phase 3, randomized study. Hepatology 2016. doi: 10.1002/hep.28467. Epub ahead of print.
dc.identifier.citedreferenceCrittenden NE, Buchanan LA, Pinkston CM, et al. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation. Liver Transpl 2016; 22: 635.
dc.identifier.citedreferenceCrespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373.
dc.identifier.citedreferenceHerzer K, Gerken G. Hepatitis C virus reinfection after liver transplant: new chances and new challenges in the era of directâ acting antiviral agents. World J Hepatol 2015; 7: 532.
dc.identifier.citedreferenceKakati B, Seetharam A. Hepatitis C recurrence after orthotopic liver transplantation: mechanisms and management. J Clin Transl Hepatol 2014; 2: 189.
dc.identifier.citedreferenceWang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferonâ based combination antiâ viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586.
dc.identifier.citedreferenceKuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant 2006; 6: 449.
dc.identifier.citedreferenceBerenguer M, Schuppan D. Progression of liver fibrosis in postâ transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028.
dc.identifier.citedreferencePungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690.
dc.identifier.citedreferenceCoilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78.
dc.identifier.citedreferenceKwo PY, Ghabril M, Lacerda MA, Joseph TA, Fridell JA, Vianna R. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis postâ orthotopic liver transplant. Clin Transplant 2014; 28: 722.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tri12896.pdf
Size:
287.5KB
Format:
PDF
View/Open
Name:
tri12896_am.pdf
Size:
354.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.